NCT03529422 2025-07-20
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
UNC Lineberger Comprehensive Cancer Center
University of Chicago
University of Kentucky
Louisiana State University Health Sciences Center Shreveport
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
SWOG Cancer Research Network